Focus on the World Diabetes Market : Analysis and Forecasts 2009-2023

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

World Diabetes Market Analysis, 2009-2023

http://www.reportlinker.com/p0109864/World-Diabetes-Market-Analysis-2009-2023.html

Incidence and prevalence of diabetes mellitus are increasing worldwide, in line
with lifestyle changes and population aging. In particular, the rising
prevalence of diabetes is closely linked with that of obesity, creating
significant market opportunities.

As discussed in this new report - World Diabetes Market Analysis, 2009-2023 -
The World Health Organization estimates the number of diabetics to exceed 350
million by 2030. Governments and other healthcare providers around the world are
investing in health education, diagnosis and treatments for this chronic,
debilitating - but controllable - disorder. In 2007, the diabetes treatment
market worldwide was worth over $25 billion, and had double-digit growth from
the year before. Consequently, it is one of the largest sectors in the global
healthcare industry. All segments of the diabetes therapy market have been
expanding, but which will grow fastest in years to come? What are the key
therapeutic and commercial trends to watch? How will the principal national
markets perform from 2009 to 2023? What will happen to the current leading
products/therapies? How does diabetes overlap with obesity?

This report will answer those and other crucial questions about this large,
increasingly important pharmaceutical market. This report - World Diabetes
Market Analysis, 2009-2023 - provides in-depth analysis of the markets for
insulins, insulin analogues and oral anti-diabetics. This report also covers the
new GLP-1 analogues - such as Byetta and liraglutide - as well as potentially
revolutionary insulin delivery technologies. Our study includes detailed sales
forecasts for crucial products and market areas, providing the information you
need to assess commercial aspects of the diabetes market fully. We cover both
sales worldwide and for leading national markets, present and future. In
addition to consultation with relevant experts - including interview transcripts
- this original research involved a detailed study of policy documents,
industrial reports and current developments, including R&D pipelines and line
extensions. Importantly,the author of this report applied techniques such as
financial forecasting and analyses of market drivers and restraints. The result
is a comprehensive market- and industry-based report with detailed analyses and
informed opinion that you will not find anywhere else.

Highlights of World Diabetes Market Analysis, 2009-2023 include:

• Analyses of the strengths, weaknesses, opportunities and threats that will
affect the global diabetes market, particularly drivers and restraints

• Sales forecasts for major drugs and discussion of prominent companies`
activities

• Separate analyses and forecasts for the oral anti-diabetics and insulin
analogues markets

• Regional analyses for the United States, Europe, Japan, China and India, all
divided into sales forecasts for oral anti-diabetics and insulin analogues

• Expert opinion - derived from original research interviews - discussing
diabetes research, promising drugs and the commercial and therapeutic
significance of the obesity epidemic on diabetes incidence and treatment,
present and future

• Analyses of crucial future trends, including ultra-long-acting drugs and novel
insulin-delivery technologies, as well as more-radical developments.

Why you should buy this report:

• To receive forecasts of global revenue trends for diabetes treatments from
2009 to 2023

• To gain in-depth sales forecasts, from 2009 to 2023, covering strengths and
weaknesses of key products and sub-markets

• To gain an understanding of all sectors of the diabetes market, including
commercial analyses of individual drugs, drug classes, pipelines and regional
markets

• To discover insight from original interviews with key opinion leaders (KOLs)

• To find out how the diabetes market is set to change dramatically over the
next fifteen years

• To discover how the diabetes management sector is evolving worldwide in terms
of diagnosis, assessment, treatment and patient compliance

• To discover exactly why diabetes is a major concern for governments, and why
this serious chronic illness is one of the most important global healthcare
issues, with hundreds of millions of people suffering from diabetes and hundreds
of million more currently at risk

It is predicted continuing expansion of the market for the whole range of
diabetes treatments, driven by increasing disease incidence as well as
improvements to diagnoses and treatment access, especially in developing
countries. Successful participating companies will benefit as a result, gaining
market prominence from high-value products. The healthcare industry cannot
afford to ignore current developments in diabetes treatment, as shown in this
report. Diabetes is arguably the greatest healthcare threat in developed
countries and a rising scourge in countries such as China, India and Brazil.
Pharmaceutical, biotechnological and diagnostics companies cannot afford to
overlook this developing field, especially for innovative therapies.

Table of Contents

1 Executive Summary

1.1 The Diabetes Market Trajectory

1.1.1 Prediction for Total Diabetes Sales in 2023

1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals is
Growing

1.1.3 Diabetes Care Works: The Market Will Expand

1.1.4 Awareness, Advocacy and Government Spending Aimed at Diabetes are all
Expanding

1.2 Aims, Scope and Format of the Report

1.3 Research Methodology

2 Introduction

2.1 What is Diabetes Mellitus?

2.1.1 Symptoms of Diabetes

2.1.2 Type 1 Diabetes

2.1.3 Type 2 Diabetes

2.1.4 Gestational Diabetes

2.1.5 Other types of Diabetes

2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic Syndrome

2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye and Nerve Damage

2.3 Obesity: The Major Diabetes Risk Factor

2.4 Other Risk Factors: Age, Genetics, Race

2.5 Diagnosis: Guidelines are Subject to Change

2.6 Prevalence: By All Measures, Diabetes Rates are Rising Epidemically

2.7 The Economic Costs of Diabetes

2.8 Treatments

2.8.1 Insulin: A Therapeutic Mainstay

2.8.2 Other Medications

2.8.3 More Novel Therapies? A New Discovery about How Insulin Works May Lead to
New Drugs

2.9 Diabetes Treatment Noncompliance Rates 25% to 90% Currently

3 World Diabetes Market, 2008-2023: Leading Drugs

3.1 Market Forecast, 2008-2023

3.2 Byetta Forecast

3.2.1 Byetta`s Strengths

3.2.2 Restraints on Byetta

3.3 Oral Antidiabetics Forecast

3.4 Actos Forecast

3.5 Avandia Forecast

3.6 Januvia Forecast

3.7 Avandamet Forecast

3.8 Human Insulin and Analogues Forecast

3.9 Lantus Forecast

3.10 Novorapid Forecast

3.11 Humalog Forecast

3.12 Novomix Forecast

3.13 Actraphane HM Forecast

3.14 Levemir Forecast

3.15 Other Diabetes-related Drugs: Symlin and Kinedak

3.16 Alternative Delivery Methods: The Possibilities to Watch

3.16.1 Exubera: Cautionary Case Study

3.16.2 Oral Delivery Technologies

3.16.3 Transdermal Technologies

4 Leading Companies in Diabetes Treatment

4.1 Novo Nordisk

4.1.1 Insulin Plant to be Built in China

4.1.2 FDA Delays Liraglutide Once-Daily

4.1.3 Teaming up with Merrion for Oral Delivery Technologies

4.2 Takeda

4.2.1 May Seek Atherosclerosis Application for Actos

4.3 sanofi-aventis

4.3.1 Patent Infringement Case with Novo Nordisk and Eli Lilly

4.4 Eli Lilly

4.4.1 Eli Lilly`s Fortunes Closely Linked to Amylin`s Performance

4.5 Amylin

4.5.1 Amylin`s Future Tied to Byetta LAR

4.6 Pipeline Developments

4.6.1 Liraglutide

4.6.2 Other GLP-1 Analogues

4.6.3 DPP-4 Inhibitors

4.6.4 Biguanides

4.6.5 New Therapy Class: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

4.6.6 Insulin Pipeline: Mostly Focused On Delivery Methods

4.6.7 Pipeline for Cures?

5 World Market Analysis by Region

5.1 United States Forecast

5.2 Europe Forecast

5.3 Japan Forecast

5.4 India Forecast

5.5 China Forecast

5.6 The Rest of the World

6 SWOT (Strengths, Weaknesses, Opportunities & Threats) Analysis

6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Are Effective

6.1.1 Diabetes is Chronic

6.1.2 Younger Patients, More Comprehensive Diagnoses

6.1.3 Prevention Inadequate

6.1.4 Drugs Often Used in Combination

6.2 Weaknesses

6.2.1 Diagnostic Inadequacies

6.2.2 Developing Countries Cannot Afford Many Newer Drugs

6.2.3 Noncompliance Rates up to 65%

6.3 Opportunities

6.3.1 Expanding Markets: India and China

6.3.2 Changing Guidelines for Diagnosing Diabetes

6.3.3 Techniques for Increasing Patient Compliance

6.3.4 Novel Drugs, Novel Delivery Methods

6.4 Threats

6.4.1 The Most-Significant Threat: Potential Changes in Drug Approval Guidelines

6.4.2 Changing FDA Guidelines for New Drug Approvals

6.4.3 Generic Erosion

6.4.4 Vaccine to Prevent Type 1 Diabetes?

6.4.5 Highly Publicised Diabetes Drugs Side Effects

6.5 Interview with Fred Levine, M.D., Ph.D., Professor, Burnham Institute for
Medical Research; Director, Sanford Children's Health Research Center

6.5.1 Alternative Delivery Methods

6.5.2 Cardiovascular Problems Associated with Oral Antidiabetics

6.5.3 Obesity and Diabetes

6.5.4 Byetta

6.5.5 Stem Cell Therapy/Cure

6.6 Interview with Björn Tyrberg, PhD., Associate Professor at Burnham Institute
for Medical Research, Diabetes and Obesity Research Center

6.6.1 Diet and Diabetes

6.6.2 Link Between Obesity and Diabetes

6.6.3 Byetta and liraglutide

7 Conclusions: Diabetes is a High Growth Market

7.1 Diabetes Increasing Worldwide: High Prevalence and Incidence

7.2 World Market Value by 2023

7.3 How will Oral Antidiabetic and Insulin Sales Compare in the Future?

List of Tables

Table 2.1 Diabetes Numbers in Millions, by WHO Region

Table 2.2 Secondary Costs of Diabetes in the US

Table 2.3 Total Costs of Diabetes to Africa

Table 2.4 Diabetes World Market, 2007

Table 2.5 Insulin Types, by Onset Rate

Table 2.6 Alternative Delivery Methods in the Pipeline, by Type and Development
Stage, 2008

Table 2.7 Antidiabetic Drugs by Class, 2008

Table 3.1 Diabetes Sales Forecast, 2008-2023

Table 3.2 Sales Forecasts for Oral Antidiabetics and Insulins, 2008-2023

Table 3.3 Byetta Sales Forecast, 2008-2023.

Table 3.4 Oral Antidiabetic Sales Forecast, 2008-2023

Table 3.5 Actos Sales Forecast, 2008-2023

Table 3.6 Avandia Sales Forecast, 2008-2023

Table 3.7 Januvia Sales Forecast, 2008-2023

Table 3.8 Avandamet Sales Forecast 2008-2023

Table 3.9 Insulin Sales Forecast 2008-2023

Table 3.10 Lantus Sales Forecast, 2008-2023

Table 3.11 Novorapid Sales Forecast, 2008-2023

Table 3.12 Humalog Sales Forecast, 2008-2023

Table 3.13 Novomix Sales Forecast, 2008-2023

Table 3.14 Actraphane HM Sales Forecast, 2008-2023

Table 3.15 Levemir Sales Forecast, 2008-2023

Table 3.16 Symlin Sales Forecast, 2008-2023

Table 3.17 Pipeline of Alternative Methods of Insulin Delivery, by Method and
Development Stage, 2008

Table 4.1 Pipeline of Alternative Insulin Delivery Methods, 2008

Table 5.1 Sales and Market Share Forecasts, 2008-2023

Table 6.1 SWOT Table for Diabetes Therapies, 2008-2023

List of Figures

Figure 2.1 Rise in Diabetes Cases, by WHO Region

Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007

Figure 2.3 Secondary Costs of Diabetes (minus direct medical costs), 2007

Figure 3.1 Total Diabetes Sales Forecast, 2008-2023

Figure 3.2 Diabetes Market, by Type and Market Share %, 2007

Figure 3.3 Sales Forecast for Oral Antidiabetics and Insulins, 2008-2023

Figure 3.4 Byetta Sales Forecast, 2008-2023

Figure 3.5 Oral Antidiabetic Sales Forecast, 2008-2023

Figure 3.6 Top Oral Antidiabetics, by Market Share, 2008

Figure 3.7 Actos Sales Forecast, 2008-2023

Figure 3.8 Avandia Sales Forecast 2008-2023

Figure 3.9 Januvia Sales Forecast, 2008-2023

Figure 3.10 Avandamet Sales Forecast, 2008-2023

Figure 3.11 Insulin Sales Forecast 2008-2023

Figure 3.12 Top-selling Insulins by Market Share

Figure 3.13 Lantus Sales Forecast, 2008-2023

Figure 3.14 Novorapid Sales Forecast, 2008-2023

Figure 3.15 Humalog Sales Forecast, 2008-2023

Figure 3.16 Novomix Sales Forecast, 2008-2023

Figure 3.17 Actraphane HM Sales Forecast, 2008-2023

Figure 3.18 Levemir Sales Forecast, 2008-2023

Figure 3.19 Symlin Sales Forecast, 2008-2023

Figure 4.1 Leading Companies by Market Share, 2007

Figure 5.1 Regional Sales Forecasts, 2008-2023

Figure 5.2 Market Share by Region, 2013

Figure 5.3 Market Share by Region, 2018

Figure 5.4 United States Sales Forecast, 2008-2023

Figure 5.5 European Sales Forecasts, 2008-2023

Figure 5.6 Japanese Sales Forecast, 2008-2023

Figure 5.7 Indian Sales Forecast, 2008-2023

Figure 5.8 Chinese Sales Forecast, 2008-2023

Figure 5.9 Rest of the World Sales Forecast, 2008-2023

Companies Listed

Abbott

Altea Therapeutics

Amylin

AstraZeneca

Aventis

Battelel Medical Device Solutions

Baxter International

Bayhill Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Burnham Institute

Chong Kun Dang

CPEX/Bentley

Diabetology

Eli Lilly

Emisphere

Forest

Galenix

Generex Biotechnology

GlaxoSmithKline

Hoechst

Human Genome Sciences

Ipsen

Lifescan

MannKind

Merck

Merrion

Novartis

Novo Nordisk

Ono

Oramed

Otsuka

Pfizer

Phenomix

Phosphagenics

Qdose

Roche

Sanofi-aventis

Servier

Takeda

Ypsomed

To order this report:

World Diabetes Market Analysis, 2009-2023

http://www.reportlinker.com/p0109864/World-Diabetes-Market-Analysis-2009-2023.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009